Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug
Administration (FDA) approved the use of Lyrica® (pregabalin)
capsules CV for the management of neuropathic pain associated with
spinal cord injury. Lyrica received a priority review designation for
this new indication from the FDA. More than 100,000 patients -
approximately 40 percent of the 270,000 patients with spinal cord injury
in the United States - suffer from this chronic, complex pain condition.
Neuropathic pain associated with spinal cord injury can be severely
debilitating and may significantly hinder rehabilitation and the ability
to regain function.
"This milestone represents an important opportunity for physicians to
more effectively manage the debilitating neuropathic pain that often
accompanies spinal cord injury," said clinical study investigator Diana
Cardenas, MD, MHA, professor and chair, department of rehabilitation
medicine, University of Miami Miller School of Medicine and chief of
service for rehabilitation medicine and medical director of Jackson
Rehabilitation Hospital, Miami, Florida. "Given the clinical challenges
of investigating neuropathic pain in this patient population, any
advancements in treatment are welcome by physicians and patients alike."
An estimated 12,000 new spinal cord injury patients are diagnosed in the
U.S. each year. There are a wide variety of causes for spinal cord
injury, including traumatic and non-traumatic causes. Traumatic causes
may include motor vehicle accidents, violence, falls and sports
injuries. In these instances, a spinal cord injury typically begins with
a sudden, traumatic blow to the spine that fractures or dislocates
vertebrae. The damage begins at the moment of injury when displaced bone
fragments, disc material, or ligaments bruise or tear into spinal cord
tissue. Non-traumatic causes may involve congenital and developmental
abnormalities, genetics and metabolism, infections and inflammation,
removal of a benign spinal tumor and spinal cord ischemic stroke.
Neuropathic pain can be experienced above, at or below the level of the
spinal cord injury, and is typically not confined to one area in the
body. Approximately one-third of spinal cord injury patients report
below-level neuropathic pain that is severe or excruciating. Patients
may experience neuropathic pain associated with spinal cord injury as
early as two weeks after injury and it may persist for up to 25 years.
"Until now, no FDA approved treatment options were available in the U.S.
for people with neuropathic pain associated with spinal cord injury, a
condition which can be extremely disabling," said Steven J. Romano, MD,
senior vice president and head, medicines development group, Global
Primary Care Business Unit, Pfizer. "The approval of Lyrica for this
indication is a significant milestone, exemplifying Pfizer's commitment
to pursue scientific advancements that address unmet medical needs."
Source: Pfizer Inc.